ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.565,75
-0,64%
S&P 500
5.306,04
0,02%
Dow Jones
38.852,86
-0,55%
Euro vs US Dollar
1,08497
-0,04%
Bitcoin
67.771,56
-0,76%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Regulus Therapeutics Inc (RGLS)

  7. Regulus Therapeutics Inc (RGLS) News

RGLS Regulus Therapeutics Inc

2,045
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:00:00
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Regulus Therapeutics Inc RGLS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 2,045 10:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,045
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
21.5.202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.5.202422:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
17.5.202423:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:02EDGAR2Form 8-K - Current report
16.5.202414:00PRNUSRegulus Therapeutics Announces Promotion of Rekha Garg,..
09.5.202422:54EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09.5.202422:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.5.202422:15EDGAR2Form 8-K - Current report
09.5.202422:05PRNUSRegulus Therapeutics Reports First Quarter 2024 Financial..
06.5.202414:00PRNUSRegulus Therapeutics Advances to Cohort 4 of Phase 1b..
30.4.202414:00PRNUSRegulus Therapeutics to Participate in the Canaccord Genuity..
21.3.202421:05PRNUSRegulus Therapeutics Reports Fourth Quarter and Year-End..
12.3.202411:32PRNUSRegulus Therapeutics Announces Oversubscribed $100 Million..
12.3.202411:30PRNUSRegulus Therapeutics Announces Positive Topline Data from..
19.1.202402:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202402:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.1.202422:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
10.1.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02.1.202422:05PRNUSRegulus Therapeutics Announces Completion of Enrollment in..
27.12.202322:16EDGAR2Form S-3 - Registration statement under Securities Act of..
22.11.202314:00PRNUSRegulus Therapeutics to Present at the 6th Annual Evercore..
09.11.202322:39EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202322:15EDGAR2Form 8-K - Current report
09.11.202322:05PRNUSRegulus Therapeutics Reports Third Quarter 2023 Financial..
02.11.202313:00PRNUSRegulus Therapeutics Announces First Patient Dosed in Third..
19.10.202314:00PRNUSRegulus Therapeutics Advances to Cohort 3 of Phase 1b..
20.9.202313:00PRNUSRegulus Therapeutics Announces Positive Topline Data from..
13.9.202314:00PRNUSRegulus Therapeutics Announces Completion of Enrollment in..
05.9.202314:00PRNUSRegulus Therapeutics Announces Participation at Two..
23.8.202314:00PRNUSRegulus Therapeutics to Host Virtual Investor Event on..
14.8.202322:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.8.202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.8.202322:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202322:15EDGAR2Form 8-K - Current report
08.8.202322:05PRNUSRegulus Therapeutics Reports Second Quarter 2023 Financial..
02.8.202314:00PRNUSRegulus Therapeutics to Present at the Canaccord Genuity..

Kürzlich von Ihnen besucht

NASDAQ
RGLS
Regulus Therapeutics
LSE
BM10
Citi Fun 26
BOV
CSXC34
CSX
USOTC
PGTRF
Pegatron (PK)
BIT
UC4KSC
Unicredit Bank
BIT
P1SD31
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten